Fu Y - Search Results

1

Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.

Hu B, Zou T, Qin W, Shen X, Su Y, Li J, Chen Y, Zhang Z, Sun H, Zheng Y, Wang CQ, Wang Z, Li TE, Wang S, Zhu L, Wang X, Fu Y, Ren X, Dong Q, Qin LX. Hu B, et al. Among authors: fu y. Cancer Res. 2022 Oct 17;82(20):3845-3857. doi: 10.1158/0008-5472.CAN-21-4140. Cancer Res. 2022. PMID: 36066408 Free PMC article.

2

The Diverse Mechanisms of miRNAs and lncRNAs in the Maintenance of Liver Cancer Stem Cells.

Zhao J, Fu Y, Wu J, Li J, Huang G, Qin L. Zhao J, et al. Among authors: fu y. Biomed Res Int. 2018 May 15;2018:8686027. doi: 10.1155/2018/8686027. eCollection 2018. Biomed Res Int. 2018. PMID: 29888282 Free PMC article. Review.

3

The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection.

Xue M, Zhou C, Zheng Y, Zhang Z, Wang S, Fu Y, Atyah M, Xue X, Zhu L, Dong Q, Jia H, Ren N, Hu R. Xue M, et al. Among authors: fu y. Aging (Albany NY). 2020 Aug 5;12(15):15566-15580. doi: 10.18632/aging.103592. Epub 2020 Aug 5. Aging (Albany NY). 2020. PMID: 32756012 Free PMC article.

4

Isolation and characterization of exosomes for cancer research.

Zhu L, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, Hu BY, Qin W, Zou TT, Fu Y, Shen XT, Zhu WW, Geng Y, Lu L, Jia HL, Qin LX, Dong QZ. Zhu L, et al. Among authors: fu y. J Hematol Oncol. 2020 Nov 10;13(1):152. doi: 10.1186/s13045-020-00987-y. J Hematol Oncol. 2020. PMID: 33168028 Free PMC article. Review.

5

The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.

Shen X, Hu B, Xu J, Qin W, Fu Y, Wang S, Dong Q, Qin L. Shen X, et al. Among authors: fu y. Cancer Biol Med. 2020 Nov 15;17(4):937-952. doi: 10.20892/j.issn.2095-3941.2020.0402. Epub 2020 Dec 15. Cancer Biol Med. 2020. PMID: 33299645 Free PMC article.

6

Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.

Sun H, Wang C, Hu B, Gao X, Zou T, Luo Q, Chen M, Fu Y, Sheng Y, Zhang K, Zheng Y, Ren X, Yan S, Geng Y, Yang L, Dong Q, Qin L. Sun H, et al. Among authors: fu y. Signal Transduct Target Ther. 2021 May 26;6(1):187. doi: 10.1038/s41392-021-00579-3. Signal Transduct Target Ther. 2021. PMID: 34035222 Free PMC article.

7

Lipid metabolism in cancer progression and therapeutic strategies.

Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, Yang J, Zheng Y, Bruns C, Zhao Y, Qin L, Dong Q. Fu Y, et al. MedComm (2020). 2020 Dec 24;2(1):27-59. doi: 10.1002/mco2.27. eCollection 2021 Mar. MedComm (2020). 2020. PMID: 34766135 Free PMC article. Review.

8

CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity.

Fu Y, Ci H, Du W, Dong Q, Jia H. Fu Y, et al. Pharmaceutics. 2022 Jan 25;14(2):275. doi: 10.3390/pharmaceutics14020275. Pharmaceutics. 2022. PMID: 35214008 Free PMC article.

9

An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.

Ci H, Wang X, Shen K, Du W, Zhou J, Fu Y, Dong Q, Jia H. Ci H, et al. Among authors: fu y. Int J Mol Sci. 2023 Feb 7;24(4):3324. doi: 10.3390/ijms24043324. Int J Mol Sci. 2023. PMID: 36834736 Free PMC article.

10

Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma.

Wang S, Zhu L, Li T, Lin X, Zheng Y, Xu D, Guo Y, Zhang Z, Fu Y, Wang H, Wang X, Zou T, Shen X, Zhang L, Lai N, Lu L, Qin L, Dong Q. Wang S, et al. Among authors: fu y. Cell Rep Med. 2024 Feb 20;5(2):101415. doi: 10.1016/j.xcrm.2024.101415. Cell Rep Med. 2024. PMID: 38382467 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18,681 results

Search Page